Table 1 Clinicopathological summary of the 12 t(X;18)-positive synovial sarcomas used in the current study
Age | Sex | Histology | MYCN | ID2 | Presentation | Recurrence | Overall survival |
|---|---|---|---|---|---|---|---|
6 months | M | Biphasic | ++ | POS | Localized | Yes | DOD |
15 years | F | Biphasic | ++ | POS | Localized | Yes | AWD |
11 years | M | Monophasic | ++ | POS | Localized | No | A |
17 years | F | Monophasic | ++ | POS | Localized | No | A |
12 years | M | Poorly-differentiated | ++ | NEG | Localized | No | A |
18 years | M | Biphasic | + | POS | Localized | Yes | A |
16 years | M | Biphasic | + | POS | Metastases | No | AWD |
10 years | M | Monophasic | + | NEG | Localized | No | A |
14 years | M | Monophasic | + | NEG | Localized | No | A |
10 years | M | Monophasic | − | NEG | Metastases | No | DOD |
13 years | M | Monophasic | − | NEG | Localized | No | A |
14 years | F | Monophasic | − | NEG | Metastases | No | DOD |
